In the Netherlands patients could continue after the start of 1983 to receive commercial concentrates provided there was written evidence of their consent.
Linked evidence
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates